Sartorius Stedim Biotech SDMHF Stock
Sartorius Stedim Biotech Price Chart
Sartorius Stedim Biotech SDMHF Financial and Trading Overview
| Sartorius Stedim Biotech stock price | 182.07 USD |
| Previous Close | 204 USD |
| Open | 192 USD |
| Bid | 181.1 USD x 100 |
| Ask | 192.66 USD x 100 |
| Day's Range | 192 - 192 USD |
| 52 Week Range | 178.3 - 264.3 USD |
| Volume | 65 USD |
| Avg. Volume | 1.62K USD |
| Market Cap | 18.68B USD |
| Beta (5Y Monthly) | 1.131 |
| PE Ratio (TTM) | 59.813084 |
| EPS (TTM) | 3.17 USD |
| Forward Dividend & Yield | 0.8 (0.41%) |
| Ex-Dividend Date | March 31, 2026 |
| 1y Target Est | N/A |
SDMHF Valuation Measures
| Enterprise Value | 20.72B USD |
| Trailing P/E | 59.813084 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 1.4 |
| Price/Sales (ttm) | 6.2583227 |
| Price/Book (mrq) | 3.9098346 |
| Enterprise Value/Revenue | 6.941 |
| Enterprise Value/EBITDA | 26.23 |
Trading Information
Sartorius Stedim Biotech Stock Price History
| Beta (5Y Monthly) | 1.131 |
| 52-Week Change | -14.66% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 264.3 USD |
| 52 Week Low | 178.3 USD |
| 50-Day Moving Average | 198.91 USD |
| 200-Day Moving Average | 216.42 USD |
SDMHF Share Statistics
| Avg. Volume (3 month) | 1.62K USD |
| Avg. Daily Volume (10-Days) | 450 USD |
| Shares Outstanding | 97.28M |
| Float | 27.6M |
| Short Ratio | N/A |
| % Held by Insiders | 71.50% |
| % Held by Institutions | 11.99% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | 40.00% |
| Payout Ratio | 0.25 |
| Last Split Factor | 6:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 8.98% |
| Operating Margin (ttm) | 19.60% |
| Gross Margin | 44.71% |
| EBITDA Margin | 26.46% |
Management Effectiveness
| Return on Assets (ttm) | 4.13% |
| Return on Equity (ttm) | 6.59% |
Income Statement
| Revenue (ttm) | 2.98B USD |
| Revenue Per Share (ttm) | 30.71 USD |
| Quarterly Revenue Growth (yoy) | 2.29% |
| Gross Profit (ttm) | 1.33B USD |
| EBITDA | 789.8M USD |
| Net Income Avi to Common (ttm) | 268.1M USD |
| Diluted EPS (ttm) | 3.21 |
| Quarterly Earnings Growth (yoy) | 2.90% |
Balance Sheet
| Total Cash (mrq) | 521.2M USD |
| Total Cash Per Share (mrq) | 5.38 USD |
| Total Debt (mrq) | 2.61B USD |
| Total Debt/Equity (mrq) | 63.11 USD |
| Current Ratio (mrq) | 1.026 |
| Book Value Per Share (mrq) | 49.106937 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 765.7M USD |
| Levered Free Cash Flow (ttm) | 256.06M USD |
Profile of Sartorius Stedim Biotech
| Country | United States |
| State | N/A |
| City | Aubagne |
| Address | Zone Industrielle Les Paluds |
| ZIP | 13781 |
| Phone | 33 4 42 84 56 00 |
| Website | https://www.sartorius.com |
| Industry | Medical Instruments & Supplies |
| Sector(s) | Healthcare |
| Full Time Employees | 10456 |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Q&A For Sartorius Stedim Biotech Stock
What is a current SDMHF stock price?
Sartorius Stedim Biotech SDMHF stock price today per share is 182.07 USD.
How to purchase Sartorius Stedim Biotech stock?
You can buy SDMHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sartorius Stedim Biotech?
The stock symbol or ticker of Sartorius Stedim Biotech is SDMHF.
Which industry does the Sartorius Stedim Biotech company belong to?
The Sartorius Stedim Biotech industry is Medical Instruments & Supplies.
How many shares does Sartorius Stedim Biotech have in circulation?
The max supply of Sartorius Stedim Biotech shares is 97.28M.
What is Sartorius Stedim Biotech Price to Earnings Ratio (PE Ratio)?
Sartorius Stedim Biotech PE Ratio is 57.43533300 now.
What was Sartorius Stedim Biotech earnings per share over the trailing 12 months (TTM)?
Sartorius Stedim Biotech EPS is 3.17 USD over the trailing 12 months.
Which sector does the Sartorius Stedim Biotech company belong to?
The Sartorius Stedim Biotech sector is Healthcare.